Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche’s Divarasib Shows Competitive Data As Monotherapy In KRAS

Executive Summary

A Phase I study showed better response and survival rates than Amgen’s Lumakras and Mirati’s Krazati, but investigators said confirmation from larger trials is needed.

You may also be interested in...



BMS Looks For Krazati KRAS Lead After Amgen’s Stumble

Success in a confirmatory study and in combination with Keytruda could seal BMS’s best-in-class claims.

BMS Looks To Expand Its Oncology Reach With Mirati Buyout

Bristol Myers Squibb will add Krazati to its oncology portfolio by buying Mirati Therapeutics in a deal worth up to $5.8bn, but needs to smooth out the so-far bumpy progress of the KRAS-targeting agent and achieve success in immunotherapy combinations.

Daiichi Sankyo Comes Out Swinging At WCLC As ADCs Steal Show

The Japanese drug maker gave multiple presentations on AstraZeneca-partnered Enhertu and other deruxtecan-based ADCs. Plus Gilead presented data on Trodelvy, Amgen showed early frontline data for Lumakras, and J&J’s EGFR-directed bispecific Rybrevant showed a 50% ORR in heavily pretreated patients.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel